Real-world evidence on prognostic value of minimal residual disease in multiple myeloma: Czech experience

Abstract

Minimal residual disease (MRD) is a sensitive measure of tumor plasma cells in the bone marrow that reflects remission status. The strong prognostic value of MRD negativity which may act as clinically valid surrogate biomarker for progressionfree (PFS) and overall survival (OS) in multiple myeloma (MM) has been demonstrated in many clinical trials including meta-analysis (Munshi et al., Blood Advances, 2020).

However, large and reliable data with long follow-up from real-world practice are still missing.